MwanzoALNOV • EPA
add
Novacyt SA
Bei iliyotangulia
€ 0.58
Bei za siku
€ 0.57 - € 0.59
Bei za mwaka
€ 0.49 - € 1.59
Thamani ya kampuni katika soko
40.30M EUR
Wastani wa hisa zilizouzwa
elfu 299.24
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
EPA
Habari za soko
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (GBP) | Jun 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 5.16M | 209.13% |
Matumizi ya uendeshaji wa biashara | 7.92M | 92.89% |
Mapato halisi | -8.85M | -112.01% |
Kiwango cha faida halisi | -171.47 | 31.41% |
Mapato kwa kila hisa | — | — |
EBITDA | -12.02M | -324.07% |
Asilimia ya kodi ya mapato | 1.22% | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (GBP) | Jun 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 32.95M | -59.69% |
Jumla ya mali | 99.40M | -24.78% |
Jumla ya dhima | 28.99M | 16.70% |
Jumla ya hisa | 70.41M | — |
hisa zilizosalia | 70.63M | — |
Uwiano wa bei na thamani | 0.58 | — |
Faida inayotokana na mali | -36.30% | — |
Faida inayotokana mtaji | -43.18% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (GBP) | Jun 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | -8.85M | -112.01% |
Pesa kutokana na shughuli | -4.54M | -59.67% |
Pesa kutokana na uwekezaji | elfu -566.50 | -212.18% |
Pesa kutokana na ufadhili | elfu -430.50 | -61.24% |
Mabadiliko halisi ya pesa taslimu | -5.56M | -112.16% |
Mtiririko huru wa pesa | -17.73M | -943.16% |
Kuhusu
Novacyt Group is an Anglo-French biotechnology group focused on clinical diagnostics, with offices in Camberley, Surrey, United Kingdom and Vélizy-Villacoublay, France. The company produces in vitro and molecular diagnostic tests, supplying assays and reagents worldwide. Its business units include Primerdesign, Microgen Bioproducts and Lab21 Healthcare.
In January 2020 the company announced that its molecular diagnostics division, Primerdesign, had launched a molecular test for the 2019 strain of SARSr-CoV. The test was approved as eligible for procurement under the World Health Organization's Emergency Use Listing process in April 2020, meaning that the test could be supplied by the United Nations and other procurement agencies supporting the COVID-19 response. In the same month Novacyt announced a collaboration with AstraZeneca, GlaxoSmithKline and the University of Cambridge to support the UK in its COVID-19 national screening programme at a new testing laboratory at the university's Anne McLaren laboratory. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
2006
Tovuti
Wafanyakazi
240
